Testing a Maintenance Drug After Brain Lymphoma Treatment

Plain-English translation of NCT05260619 on ClinicalTrials.gov ↗ · Source last updated March 2022 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing as a maintenance therapy for patients with primary central nervous system lymphoma (a cancer of immune cells in the brain) who have responded well to initial chemotherapy. After you complete your first round of high-dose chemotherapy and achieve a good response, you would take the medication daily for up to one year to try to keep the cancer from coming back.

Primary central nervous system lymphoma is a rare and serious cancer, and patients who cannot receive stem cell transplants or whole-brain radiation need other options to prevent their cancer from returning after initial treatment. This trial is testing whether this maintenance medication can help improve long-term outcomes for these patients.

Do you qualify?

You likely qualify if…

you have been diagnosed with primary central nervous system lymphoma that has been confirmed by a tissue sample
your cancer responded well (partial or complete response) to your first round of chemotherapy
you are not eligible for stem cell transplant or whole-brain radiation as next-step treatment
your blood cell counts and kidney, liver, and heart function are within acceptable ranges
you are willing to use two forms of birth control if you can become pregnant, or use condoms if you are male

You likely don't qualify if…

you are pregnant or breastfeeding
you have HIV, active Hepatitis B or C, or an uncontrolled infection requiring IV antibiotics
you have lymphoma outside the brain and nervous system
you have had a previous cancer diagnosis
you have had a severe allergic reaction or skin rash to this medication in the past

What participation looks like

You would start the medication about six weeks after finishing your initial chemotherapy, taking a pill by mouth daily for 21 days out of every 28-day cycle, continuing for up to 12 cycles (about one year). You would have brain MRI scans every three months to check how well the treatment is working and to watch for any side effects. You would need regular blood work and visits with your care team throughout the trial.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Trial locations(1 site)

South Korea

Seoul National University Bundang Hospital, Seongnam-si, Please Select